Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.
Wegovy, Zepbound Prices Drop, But Most Patients Still Can’t Afford Long-Term Use: ‘Coverage Is Not The Same As Access,’ Says Expert
